Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813 | See Remarks | February 10, 2020 | February 12, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dianthus Therapeutics, Inc. /DE/
Report date February 10, 2020 · Filed February 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.28 · Expires 2030-02-09 | Direct | 75,000 |
Reported balance
After 2020-02-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-10 · Grant · Acquired 75,000 · Balance 75,000 F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Foundation Medicine, Inc.
Report date July 31, 2018 · Filed August 02, 2018
Section 16 reporting ended · disclosed 2018-08-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-07-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-07-31 · Other · Disposed 6,955 · Balance 42,215 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. Row 2 · 2018-07-31 · Other · Disposed 42,215 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units. |
| stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.12 · Expires 2023-05-21 | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-07-31 · Other · Disposed 1,562 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F4: The amount reported represents the number of vested stock options cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share minus the per share exercise price of the vested stock options, multiplied by (2) the number of shares represented by such vested stock options, without interest and less any required withholding taxes. F5: This option was granted on May 21, 2013 and vested in equal quarterly installments beginning on April 1, 2014 until fully vested on January 1, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company.
F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche.
F3: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units.
F4: The amount reported represents the number of vested stock options cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share minus the per share exercise price of the vested stock options, multiplied by (2) the number of shares represented by such vested stock options, without interest and less any required withholding taxes.
F5: This option was granted on May 21, 2013 and vested in equal quarterly installments beginning on April 1, 2014 until fully vested on January 1, 2018.
GeneDx Holdings Corp.
Report date June 18, 2026 · Filed June 23, 2026
Section 16 reporting ended · disclosed 2026-06-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 15,480 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 3,576 · Balance 15,480 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Exercise / conversion · Disposed 3,576 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Jason Ryan 2024 GRAT | 103,284 |
Reported balance
Holding disclosure · report date 2026-06-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 103,284 F2: The securities in this row are held directly by the Jason Ryan 2024 GRAT U/A DTD 11/7/2024, of which the Reporting Person is trustee and sole annuitant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The securities in this row are held directly by the Jason Ryan 2024 GRAT U/A DTD 11/7/2024, of which the Reporting Person is trustee and sole annuitant.
F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
Singular Genomics Systems, Inc.
Report date February 21, 2025 · Filed February 25, 2025
Section 16 reporting ended · disclosed 2025-02-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $672.90 · Expires 2031-05-05 | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-21 · Disposition to issuer · Disposed 1,333 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F2: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.80 · Expires 2032-05-26 | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-21 · Disposition to issuer · Disposed 1,541 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F2: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.80 · Expires 2033-05-25 | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-21 · Disposition to issuer · Disposed 2,466 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F2: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.16 · Expires 2034-05-29 | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-21 · Disposition to issuer · Disposed 2,466 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F2: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.
F2: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.
SomaLogic, Inc.
Report date January 05, 2024 · Filed January 10, 2024
Section 16 reporting ended · disclosed 2024-01-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74 · Expires 2033-06-07 | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-05 · Disposition to issuer · Disposed 185,400 · Balance 0 F2: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"); and F3: (Continued from Footnote 2) each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001 (the "Parent Common Stock"), F4: (Continued from Footnote 3) rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F1: The option vests as to 1/4th of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74 · Expires 2033-06-07 | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-05 · Disposition to issuer · Disposed 14,650 · Balance 0 F2: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"); and F3: (Continued from Footnote 2) each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001 (the "Parent Common Stock"), F4: (Continued from Footnote 3) rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F5: The option shall be 100% vested on June 8, 2024, subject to the continued service of the Reporting Person on such vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-05 · Disposition to issuer · Disposed 3,400 · Balance 0 F6: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F8: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F7: The RSUs shall be 100% vested on June 8, 2024, subject to the continued service of the Reporting Person on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/4th of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
F2: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"); and
F3: (Continued from Footnote 2) each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001 (the "Parent Common Stock"),
F4: (Continued from Footnote 3) rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions.
F5: The option shall be 100% vested on June 8, 2024, subject to the continued service of the Reporting Person on such vesting date.
F6: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration.
F7: The RSUs shall be 100% vested on June 8, 2024, subject to the continued service of the Reporting Person on such vesting date.
F8: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2017 Filed Jun 6, 2017 16:33 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 5,573 | $40.00 | $222,920.00 |
DisclosureSEC source: 0001209191-17-038131 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,405 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| May 01, 2017 Filed May 3, 2017 16:02 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | GrantCommon Stock | 32,734 | $35.80 | $1,171,877.20 |
DisclosureSEC source: 0001209191-17-029603 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,978 F1 · shares: Represents restricted stock units issued pursuant to a Restricted Stock Unit Award Agreement and the Issuer's 2013 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in equal quarterly installments over a three-year period with the first installment vesting on August 1, 2017. Read SEC document |
| April 18, 2017 Filed Apr 20, 2017 16:06 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 503 | $34.55 | $17,378.65 |
DisclosureSEC source: 0001209191-17-027677 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,244 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. The sale of these shares were effected to cover tax liabilities of the reporting person in connection with the vesting and release of restricted stock units. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 16:07 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 1,233 | $31.96 | $39,406.68 |
DisclosureSEC source: 0001209191-17-025581 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,747 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on April 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 16:03 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | Exercise / conversionstock option (right to buy) · Derivative | 9,250 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001209191-17-021686 · doc4.xml · derivative · entry 5 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,250 shares Expires 2023-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on March 7, 2013 and vested in equal quarterly installments beginning on June 7, 2013 until fully vested on March 7, 2017. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 16:03 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | Exercise / conversionstock option (right to buy) · Derivative | 3,250 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-17-021686 · doc4.xml · derivative · entry 4 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,250 shares Expires 2022-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on March 27, 2012 and vested in equal quarterly installments beginning on June 27, 2012 until fully vested on March 27, 2016. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 16:03 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 12,500 | $31.68 | $396,000.00 |
DisclosureSEC source: 0001209191-17-021686 · doc4.xml · nonDerivative · entry 3 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,980 F1 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.53 to $31.95, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 16:03 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | Exercise / conversionCommon Stock | 9,250 | $4.16 | $38,480.00 |
DisclosureSEC source: 0001209191-17-021686 · doc4.xml · nonDerivative · entry 2 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 16:03 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | Exercise / conversionCommon Stock | 3,250 | $0.84 | $2,730.00 |
DisclosureSEC source: 0001209191-17-021686 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2017 Filed Jan 18, 2017 16:16 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 1,777 | $19.00 | $33,763.00 |
DisclosureSEC source: 0001209191-17-004119 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,980 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. The sale of these shares were effected to cover tax liabilities of the reporting person in connection with the vesting and release of restricted stock units. Read SEC document |
| January 04, 2017 Filed Jan 5, 2017 16:10 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 1,426 | $18.49 | $26,366.74 |
DisclosureSEC source: 0001209191-17-001986 · doc4.xml · nonDerivative · entry 2 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,757 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on January 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F5 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 16:10 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 3,239 | $17.41 | $56,390.99 |
DisclosureSEC source: 0001209191-17-001986 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,183 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on December 30, 2016. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold as part of a group sale of shares in multiple transactions at prices ranging from $17.41 to $17.56, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F3 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on July 15, 2015 in Table I of the Form 4 filed on July 17, 2015. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| October 20, 2016 Filed Oct 24, 2016 16:03 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 506 | $22.45 | $11,359.70 |
DisclosureSEC source: 0001209191-16-146726 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,422 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. The sale of these shares were effected to cover tax liabilities of the reporting person in connection with the vesting and release of restricted stock units. Read SEC document |
| October 04, 2016 Filed Oct 5, 2016 16:09 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 1,220 | $23.65 | $28,853.00 |
DisclosureSEC source: 0001209191-16-144879 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,928 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on October 1, 2016. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold as part of a group sale of shares in multiple transactions at prices ranging from $23.31 to $23.72, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F3 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.